Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

259 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations.
Blasi M, Kuon J, Lüders H, Misch D, Kauffmann-Guerrero D, Hilbrandt M, Kazdal D, Falkenstern-Ge RF, Hackanson B, Dintner S, Faehling M, Kirchner M, Volckmar AL, Kopp HG, Allgäuer M, Grohé C, Tufman A, Reck M, Frost N, Stenzinger A, Thomas M, Christopoulos P. Blasi M, et al. Eur J Cancer. 2024 Mar;199:113556. doi: 10.1016/j.ejca.2024.113556. Epub 2024 Jan 17. Eur J Cancer. 2024. PMID: 38271745 Free article.
Real-world data for precision cancer medicine-A European perspective.
Christopoulos P, Schlenk R, Kazdal D, Blasi M, Lennerz J, Shah R, Budczies J, Malek N, Fröhling S, Rosenquist R, Schirmacher P, Bozorgmehr F, Kuon J, Reck M, Thomas M, Stenzinger A. Christopoulos P, et al. Among authors: blasi m. Genes Chromosomes Cancer. 2023 Sep;62(9):557-563. doi: 10.1002/gcc.23135. Epub 2023 Mar 9. Genes Chromosomes Cancer. 2023. PMID: 36852573
Corrigendum to "First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations" [Eur J Cancer 199 (2024) 113556].
Blasi M, Kuon J, Lüders H, Misch D, Kauffmann-Guerrero D, Hilbrandt M, Kazdal D, Falkenstern-Ge RF, Hackanson B, Dintner S, Faehling M, Kirchner M, Volckmar AL, Kopp HG, Allgäuer M, Grohé C, Tufman A, Reck M, Frost N, Stenzinger A, Thomas M, Christopoulos P. Blasi M, et al. Eur J Cancer. 2024 Jul;205:114130. doi: 10.1016/j.ejca.2024.114130. Epub 2024 May 24. Eur J Cancer. 2024. PMID: 38789333 No abstract available.
KRAS and TP53 co-mutation predicts benefit of immune checkpoint blockade in lung adenocarcinoma.
Budczies J, Romanovsky E, Kirchner M, Neumann O, Blasi M, Schnorbach J, Shah R, Bozorgmehr F, Savai R, Stiewe T, Peters S, Schirmacher P, Thomas M, Kazdal D, Christopoulos P, Stenzinger A. Budczies J, et al. Among authors: blasi m. Br J Cancer. 2024 Aug;131(3):524-533. doi: 10.1038/s41416-024-02746-z. Epub 2024 Jun 12. Br J Cancer. 2024. PMID: 38866964 Free PMC article.
A novel clinical brain prognostic index for KRAS-mutated lung cancer and brain metastases (KRAS-BPI): Real-world evidence from two large European centers.
Zerdes I, Kamali C, Johannsdottir B, Blasi M, Assmann C, Kazdal D, Stenzinger A, Skribek M, Ekman S, Christopoulos P, Tsakonas G. Zerdes I, et al. Among authors: blasi m. Lung Cancer. 2024 Dec 17;199:108065. doi: 10.1016/j.lungcan.2024.108065. Online ahead of print. Lung Cancer. 2024. PMID: 39705826 Free article.
Primary suppurative thyroiditis in a non-immunocompromised patient.
Llompart Coll MM, Blasi MM, Bodro M, Vidal O. Llompart Coll MM, et al. Among authors: blasi mm. Cir Esp (Engl Ed). 2024 Dec 13:S2173-5077(24)00276-X. doi: 10.1016/j.cireng.2024.11.009. Online ahead of print. Cir Esp (Engl Ed). 2024. PMID: 39675671 No abstract available.
259 results